Streetbeat News

IGXT

IntelGenx Technologies Corp

http://www.intelgenx.com

CEO

Horst Zerbe

Employees

Industry

Pharmaceutical Preparation Manufacturing

Open

0.16

Mkt cap

30M

Volume

37K

High

0.17

P/E Ratio

-2.83

52-wk high

0.20

Low

0.16

Div yield

N/A

52-wk low

0.10

Intelgenx Technologies reported Q3 earnings with losses of $(0.01) per share, a 50% improvement from $(0.02) per share YoY. The company also reported a 123.94% increase in sales to $318.00K from $142.00K YoY.

Portfolio Pulse from bharat@benzinga.com

November 09, 2023 | 9:32 pm

IntelGenx Corp. and Tilray Brands Inc. have entered into a second amendment to their November 2018 license, development and supply agreement for the co-development and commercialization of cannabinoid-infused VersaFilm products. The amendment settles IntelGenx's arbitration claim against Tilray and includes an initial purchase order from Tilray for three SKUs. The agreement also allows for IntelGenx's co-development and commercialization of CBD, THC, and combination THC:CBD products with additional partners, and removes any royalties paid to or from Tilray.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:34 pm

IntelGenx Technologies Corp. reported a 67% decrease in total revenues for Q2 2023, with operating costs rising slightly. The company also reported a net comprehensive loss of $3.0 million for the quarter. Despite these financial setbacks, the company has achieved significant milestones, including completing enrollment in the BUENA study and signing a binding term sheet with a CDMO customer for oral film packaging services, expected to yield around $9 million over three years.

Portfolio Pulse from Nicolás Jose Rodriguez

August 15, 2023 | 2:54 am

Intelgenx Technologies reported Q2 earnings with losses of $(0.02) per share, unchanged YoY. Sales were $133.00K, a 66.58% decrease from $398.00K YoY.

Portfolio Pulse from vinayak@benzinga.com

August 14, 2023 | 8:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.